Literature DB >> 17721502

Argon laser photocoagulation for the treatment of polypoidal choroidal vasculopathy.

M-W Lee1, I Yeo, D Wong, C-L Ang.   

Abstract

AIM: To evaluate the efficacy of conventional argon laser for the treatment of serosanguineous maculopathy secondary to polypoidal choroidal vasculopathy (PCV).
METHODS: A retrospective audit of patients who had argon laser photocoagulation to angiographically determined polypoidal lesions and subsequently followed up at 1, 3, 6, and 12 months post treatment.
RESULTS: Twenty-one eyes (75%) had stable or improved vision at 12 months. Twenty-three eyes had extrafoveal, two eyes had juxtafoveal, and three eyes had subfoveal polyps. In the extrafoveal group, 18 eyes (78%) had stable or improved vision at 12 months. Eighteen eyes (64.3%) showed clinical or angiographic resolution of maculopathy. Three eyes (10.7%) had recurrence of polyps subfoveally, three eyes (10.7%) had subsequent choroidal neovascularisation, and four eyes (14.3%) had persistent leakage with neurosensory detachment.
CONCLUSION: In our study, 18 of the 23 eyes which had extrafoveal polyps had stable or improved best-corrected visual acuity and showed complete resolution of maculopathy at 12 months follow-up. Argon laser photocoagulation would appear to be most beneficial for extrafoveal PCV. However, in view of the retrospective nature of this study, the true efficacy of argon laser treatment would have to be evaluated with a larger, prospective and randomised controlled trial.

Entities:  

Mesh:

Year:  2007        PMID: 17721502     DOI: 10.1038/sj.eye.6702955

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  16 in total

1.  Assessment of focal laser photocoagulations' early effect on polypoidal choroidal vasculopathy with optical coherence tomography angiography.

Authors:  Erdem Eriş; İrfan Perente; Esra Vural; Dilek Yaşa; Abdullah Ozkaya
Journal:  Lasers Med Sci       Date:  2018-03-02       Impact factor: 3.161

2.  Clinical features, management and visual outcome of polypoidal choroidal vasculopathy in Indian patients.

Authors:  Giridhar Anantharaman; Gudapati Ramkumar; Mahesh Gopalakrishnan; Alpesh Rajput
Journal:  Indian J Ophthalmol       Date:  2010 Sep-Oct       Impact factor: 1.848

Review 3.  Photodynamic therapy: current role in the treatment of chorioretinal conditions.

Authors:  D K Newman
Journal:  Eye (Lond)       Date:  2016-01-08       Impact factor: 3.775

4.  Polypoidal Choroidal Vasculopathy.

Authors:  Raquel Goldhardt; Bradley Simon Rosen
Journal:  Curr Ophthalmol Rep       Date:  2019-02-02

Review 5.  Polypoidal Choroidal Vasculopathy in Asians.

Authors:  Chee Wai Wong; Tien Y Wong; Chui Ming Gemmy Cheung
Journal:  J Clin Med       Date:  2015-04-24       Impact factor: 4.241

6.  Treatment Outcomes in Patients with Polypoidal Choroidal Vasculopathy.

Authors:  Işıl Sayman Muslubaş; Mümin Hocaoğlu; Serra Arf; Hakan Özdemir; Murat Karaçorlu
Journal:  Turk J Ophthalmol       Date:  2016-01-05

7.  A case of polypoidal choroidal vasculopathy. Periphery is equally important for such patients.

Authors:  Dimitrios A Karagiannis; Vasilios Soublis; Artemios Kandarakis
Journal:  Clin Interv Aging       Date:  2009-06-29       Impact factor: 4.458

8.  Intravitreal Anti-vascular Endothelial Growth Factor for Newly Diagnosed Symptomatic Polypoidal Choroidal Vasculopathy with Extrafoveal Polyps.

Authors:  Jae Hui Kim; Dong Won Lee; Sung Chan Choi; Jong Woo Kim; Tae Gon Lee; Chul Gu Kim; Han Joo Cho
Journal:  Korean J Ophthalmol       Date:  2015-11-25

Review 9.  Polypoidal choroidal vasculopathy: an update on therapeutic approaches.

Authors:  Raymond L M Wong; Timothy Y Y Lai
Journal:  J Ophthalmic Vis Res       Date:  2013-10

10.  Management of significant reactivation of old disciform scars in wet age-related macular degeneration.

Authors:  Rosa M Coco; Anna Sala-Puigdollers
Journal:  BMC Ophthalmol       Date:  2014-06-25       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.